CORE-SHELL PARTICLE FORMULATION FOR DELIVERING MULTIPLE THERAPEUTIC AGENTS
A core-shell particle formulation for delivering multiple therapeutic agents is disclosed. More particularly, core-shell particle formulation configured to independently release therapeutic agents from the core and the shell. Moreover, the core-shell particle bearing therapeutic agents enables treatment against the diseases such as cancer, inflammatory and auto-immune diseases.
1 . A core-shell particle formulation for delivering multiple therapeutic agents comprising:
one or more polymers forming a core, wherein the one or more polymers forming the core comprise poly(lactic-co-glycolic acid); and
one or more proteins forming a shell encapsulating the core to form a particle formulation, wherein the one or more proteins forming the shell comprise serum albumin;
wherein the core and the shell each comprise one or more therapeutic agents;
wherein the particle formulation is configured to independently release the therapeutic agents from the core and the shell; and
wherein the therapeutic agents are configured to be delivered by active targeting, wherein the active targeting is done by conjugating the core-shell formulation with transferrin ligand or EGFR.
2 . The formulation of claim 1 , wherein the one or more therapeutic agents of the core comprise doxorubicin and the one or more therapeutic agents of the shell comprise sorafenib.
3 . The formulation of claim 1 , wherein the one or more therapeutic agents of the core comprise sorafenib and the one or more therapeutic agents of the shell comprise doxorubicin.
4 . The formulation of claim 1 , wherein the one or more therapeutic agents of the core comprise dasatinib and the one or more therapeutic agents of the shell comprise sorafenib.
5 . The formulation of claim 1 , wherein the one or more therapeutic agents of the core comprise sorafenib and the one or more therapeutic agents of the shell comprise dasatinib.
6 . The formulation of claim 1 , wherein the core is of average size ≦500 nm.
7 . The formulation of claim 1 , wherein the shell is of average thickness ≦200 nm.
8 . The formulation of claim 1 , wherein the therapeutic agents are configured to be delivered from the shell and core sequentially.
9 . The formulation of claim 1 , wherein the therapeutic agents are configured to be delivered from the shell and core simultaneously.
10 . A core-shell particle formulation for delivering multiple therapeutic agents comprising:
one or more polymers forming a core, wherein the one or more polymers forming the core comprise poly vinyl alcohol; and
one or more proteins forming a shell encapsulating the core to form a particle formulation, wherein the one or more proteins forming the shell comprise protamine;
wherein the core and the shell each comprise one or more therapeutic agents;
wherein the particle formulation is configured to independently release the therapeutic agents from the core and the shell; and
wherein the therapeutic agents are configured to be delivered by active targeting, wherein the active targeting is done by conjugating the core-shell formulation with transferrin ligand or EGFR.
11 . The formulation of claim 10 , wherein the one or more therapeutic agents of the core comprise doxorubicin and the one or more therapeutic agents of the shell comprise sorafenib.
12 . The formulation of claim 10 , wherein the one or more therapeutic agents of the core comprise sorafenib and the one or more therapeutic agents of the shell comprise doxorubicin.
13 . The formulation of claim 10 , wherein the one or more therapeutic agents of the core comprise dasatinib and the one or more therapeutic agents of the shell comprise sorafenib.
14 . The formulation of claim 10 , wherein the one or more therapeutic agents of the core comprise sorafenib and the one or more therapeutic agents of the shell comprise dasatinib.
15 . The formulation of claim 10 , wherein the core is of average size ≦500 nm.
16 . The formulation of claim 10 , wherein the shell is of average thickness ≦200 nm.
17 . The formulation of claim 10 , wherein the therapeutic agents are configured to be delivered from the shell and core sequentially.
18 . The formulation of claim 10 , wherein the therapeutic agents are configured to be delivered from the shell and core simultaneously.